Skip to main content
MedPathMedPath Home
Clinical Trials/ITMCTR1900002782
ITMCTR1900002782
Not yet recruiting
未知

Study for the regulation mechanism of body immune function by meditation

Beijing University of Chinese Medicine0 sitesTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Beijing University of Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational study
Sex
All

Investigators

Sponsor
Beijing University of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • •(1\) healthy physical examination (routine hematuria and stool, liver and kidney function \+ blood lipid), and did not complain of obvious discomfort;
  • •(2\) Aged 20 to 60 years old;
  • •(3\) BMI 18\.5 to 23\.9;
  • •(4\) nearly 3 months did not use antibiotics;
  • •(5\) have not used gastrointestinal motility drugs, acid\-suppressants, microecological preparations or immunosuppressants in the past 3 weeks;
  • •(6\) subjects in the meditation group received meditation training for more than 3 years;
  • •(7\) the subjects in the control group have never received any form of meditation training (such as qigong, yoga, taijiquan, baduanjin, etc.);
  • •(8\) agree to participate in the study and sign informed consent.

Exclusion Criteria

  • •(1\) with serious mental and psychological diseases and major chronic diseases;
  • •(2\) pregnancy or lactation period;
  • •(3\) a history of alcohol or drug abuse;
  • •(4\) is participating in other clinical researchers.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Pilotstudy about the role of regulatory immune cells in autoimmunity, cancer and organ rejection after kidney transplantatioE10M06M32M34C18Z94.0Type 1 diabetes mellitusOther rheumatoid arthritisSystemic lupus erythematosusSystemic sclerosisMalignant neoplasm of colonKidney transplant status
DRKS00026238Medizinische Universität Graz, Department für Innere Medizin, Abteilung für Endokrinologie und Diabetologie485
Active, not recruiting
Phase 1
Mechanistic study assessing the immunological response of subjects after treatment with different formulations of sublingual immunotherapy. - Assessing the immunological response after sublingual immunotherapy
EUCTR2006-002123-17-GBImperial College London30
Completed
Not Applicable
Exploratory study on mechanism of action and immune-related biomarkers in patients with salivary gland cancer who received trastuzumab delxtecasalivary gland carcinoma
JPRN-UMIN000044278Hokkaido University Hospital Medical oncology52
Not yet recruiting
Phase 1
Study for Immune Molecular Mechanism in the Treatment of Sequelae of Pelvic Inflammatory Disease of Accumulated Damp Heat with Penyanxiao in Combination with Pelvic Perfusio
ITMCTR2000002965Xianyang Central Hospital
Active, not recruiting
Phase 1
Immunomonitoring anti-PD1 dans le mélanome métastatiqueAdvanced metastatic melanoma in adultsMedDRA version: 18.0Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2014-003120-48-FRHospices Civils de Lyon40